<DOC>
	<DOCNO>NCT02176018</DOCNO>
	<brief_summary>The purpose study evaluate efficacy effectiveness daily dextromethorphan/quinidine ( Nuedexta ) reduce frequency progression episodic migraine .</brief_summary>
	<brief_title>Nuedexta Prevention Modification Disease Progression Episodic Migraine</brief_title>
	<detailed_description>This double-blind , placebo-controlled , randomize , multi-center study conduct Headache Care Center Springfield , MO two clinic United States . Approximately 45 subject , 18 65 year age , frequent episodic migraine ( 6-14 day per month ) , ( 1.2 ) without aura ( 1.1 ) define ICHD-3beta , enter 1-month baseline period confirm migraine diagnosis , well establish baseline characteristic . At Visit 1 , subject must history utilization acute treatment great 14 day per month precede 3 month period . Subjects must current history ICHD-3beta migraine 6-14 migraine day per month 3 month prior study enrollment . Eligible subject randomly assign one two group 1:1 ratio . Randomization occur use computer-generated allocation schedule . Subjects meet entrance criterion determine screen review baseline headache diary give low available allocation number site . Migraine preventative use permit subject stable least 2 month prior screen fail 3 migraine preventative due lack efficacy . The study consist 5 office visit per subject : Visit 1 - screening , Visit 2 - randomization , Visits 3 5 - three-month treatment period . During baseline period , subject treat migraine current preferred acute treatment choice .</detailed_description>
	<mesh_term>Migraine Disorders</mesh_term>
	<mesh_term>Disease Progression</mesh_term>
	<mesh_term>Dextromethorphan</mesh_term>
	<mesh_term>Quinidine</mesh_term>
	<mesh_term>Quinidine gluconate</mesh_term>
	<criteria>male female , otherwise good health , 18 65 year age . history frequent episodic migraine least 3 month define 614 migraine day per month without aura accord ICHD3beta migraine treat ergot triptan result relief . onset migraine age 50. stable history headache least 3 month prior screen . use daily migraine preventive medication migraine medical condition ( e.g . propranolol use hypertension ) stable dose regimen least 2 month prior begin baseline period . female , childbearing potential , agree maintain true abstinence use ( partner use ) one list method birth control duration study : hormonal contraceptive , intrauterine device ( IUD ) , condom , diaphragm , and/or vasectomy . The use barrier contraceptive ( condom diaphragm ) always supplement use spermicide . Note : To consider childbearing potential , subject must 6 week postsurgical bilateral oophorectomy , hysterectomy , bilateral tubal ligation , postmenopausal least one year . unable understand study requirement , informed consent , complete headache record require per protocol . pregnant , actively try become pregnant , breastfeed . female childbearing potential use adequate contraceptive measure . experience follow migraine variant : basilar migraine , aura without headache , familial hemiplegic migraine , complicate migraine , ophthalmoplegic migraine retinal migraine . history Medication Overuse Headache ( Appendix II ) 3 month prior study enrollment baseline phase . history acute migraine treatment great 14 day per month 3 month prior screen . history 3 fail preventative medication due lack efficacy prophylactic treatment migraine adequate therapeutic trial . receive onabotulinumtoxinA injection within 3 month prior screen and/or receive onabotulinumtoxinA injection study . abuse , opinion Investigator , follow drug , currently within past 1 year : opioids , alcohol , barbiturate , benzodiazepine , cocaine . take , plan take : monoamine oxidase inhibitor ( MAOI ) include herbal preparation contain St. John 's wort ( Hypericum perforatum ) within 14 day Visit 1 , concomitant medication and/or food contain dextromethorphan , quinidine , quinine , mefloquine , paxil , dicyclomine , digitalis , thioridazine pimozide ( medication prolong QT interval ) anytime within 2 week prior screen 2 week post final study treatment . history hypersensitivity medication contain dextromethorphan . history hypersensitivity medication food contain quinidine . increase risk develop serotonin syndrome , opinion investigator . history impaired hepatic renal function , investigator 's opinion , contraindicate participation study . unstable neurological condition significantly abnormal neurological examination focal sign sign increase intracranial pressure . cardiovascular disease ( ischemic heart disease , include angina pectoris , myocardial infarction , document silent ischemia , Prinzmetal 's angina ) ; symptom ischemic heart disease , ischemic abdominal syndrome , peripheral vascular disease Raynaud 's Syndrome . ECG result outside normal limit ( &gt; 470 msec ) , prolong QT interval , congenital long QT syndrome , torsades de pointes , complete AV block . uncontrolled hypertension ( â‰¥ 140/90mmHg either systolic diastolic measurement 2 3 BP reading screen ) . serious illness , unstable medical condition , one could require hospitalization , could increase risk adverse event , opinion investigator . psychiatric disorder psychotic feature psychiatric disorder stable well control , would interfere ability complete study activity . receive investigational agent within 30 day prior Visit 1. plan participate another clinical study time study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Episodic Migraine</keyword>
	<keyword>Migraine</keyword>
	<keyword>Headache</keyword>
</DOC>